$PG

Abd El Hak Hesham sold $278K of PG

Abd El Hak Hesham (CEO-Baby and Feminine Care) sold 1,936 shares of PROCTER & GAMBLE Co (PG) at $143.79 ($0.28M total) on 2026-08-20.

Original reporting
SEC EDGAR · Abd El Hak Hesham
Published Aug 24, 2026, 7:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PG
Bearish
medium confidence
Mentioned
$PG
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGBearishLow
01

Why it matters

The disclosure provides fresh data on insider activity, which traders may use to gauge sentiment.

02

Market read

First-report insider sale; modest size but involves a senior executive, offering limited trading relevance.

03

What to watch

Potential tax planning or liquidity needs unrelated to company outlook.

Relevance 4/10Novelty 4/10Timing: filed Aug 24, transaction dated Aug 20

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the CEO's sale.

Company-level read

Ticker impact

$PGBearishMedium confidence
Context

CEO Abd El Hak Hesham sold 1,936 Procter & Gamble shares at $143.79 each, total $278,377.

Expected impact

possible short-term dip

Evidence & confidence

The sale size is modest but involves the CEO; markets often react negatively to insider disposals.

Market effects

Minimal impact on consumer staples sector; may prompt scrutiny of executive confidence.

None

Low

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Abd El Hak Hesham

    CEO of Procter & Gamble's Baby and Feminine Care division

  • Procter & Gamble Co

    Consumer goods conglomerate (ticker PG)

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PGMed

P&G Is Betting $3.8 Billion on Wellness. Can It Offset a $1 Billion Cost Headwind?

Procter & Gamble (PG) reported fiscal 2026 organic sales growth of 1% and core EPS of $6.89. For fiscal 2027, PG guided organic sales growth of 1% to 3% and core EPS growth of 0% to 3%, citing a $1 billion cost headwind from higher raw materials, energy, and transportation costs. PG acquired Thorne, a premium supplements brand, to offset some pressure. Analysts estimate a target price of $180, implying 22.7% upside over 2.8 years. PG's performance is compared to peers like Colgate-Palmolive (CL)

$PGLow

Procter & Gamble Margins Under Pressure: Time to Stay Cautious?

Procter & Gamble (PG) faces margin pressure from rising costs, expecting a $1.4B after-tax earnings headwind in fiscal 2027. Despite productivity initiatives, Q1 EPS is forecast to decline 5%. Competitors Colgate-Palmolive (CL) and Clorox (CLX) are also implementing cost-saving measures. PG's stock is up 1.7% in 3 months, trading at a forward P/E of 20.72X.

$PGMed

Weather Dividend Stocks That Keep Writing Bigger Checks

Procter & Gamble (PG) raised its dividend for 70 consecutive years, with fiscal 2026 free cash flow of $15.835B. Coca-Cola (KO) reported 5% unit case volume growth, its strongest in 17 years. Colgate-Palmolive (CL) saw 16.12% YTD stock growth and raised its dividend. All three companies demonstrated recession-resilient cash flows and dividend increases.

$PGMed

Toilet paper becomes an issue for Trump again as Canada's tariffs could spell another shortage

Canada imposed 25-50% tariffs on U.S. paper products, including toilet paper, in response to U.S. tariffs on Canadian goods. Procter & Gamble (P&G) expects a $0.25-per-share earnings hit and plans price increases. Canada supplied $328M of toilet paper to the U.S. in 2024, with Canadian pulp crucial for U.S. production. U.S. consumers bear 96% of tariff costs, per Fed research.

$PGMed

Procter & Gamble outlook raised to positive by Moody’s on cash flow

Moody’s affirmed Procter & Gamble’s (PG) ratings and changed the outlook to positive, citing strong cash flow, earnings growth, and stable credit metrics. The upgrade reflects P&G’s ability to generate positive free cash flow and earnings growth through pricing, innovation, and cost savings. Moody’s expects leverage to rise slightly due to the Thorne acquisition but return to low levels through optimization. The ratings could be upgraded if P&G maintains its strong operating profile and profitab